Gilead Sciences Announces First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Gilead Sciences (GILD) PT Raised to $76 at BMO Capital Following 1Q
May 3, 2017 9:17 AM EDTBMO Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $75.00) while maintaining a Market Perform rating. GILD reported 1Q revenues of $6.5bn, below the Street's estimates of $6.62bn, as continued strength from HIV could not off-set further deterioration in HCV.
GILD... More
Gilead Sciences (GILD) Misses Q1 EPS by 5c; Reiterates Full Year 2017 Guidance
May 2, 2017 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.23, $0.05 worse than the analyst estimate of $2.28. Revenue for the quarter came in at $6.505 billion versus the consensus estimate of $6.62 billion.
Reiterates Full Year 2017 Guidance
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... More